VERA
Vera TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful near‑term clinical data and clearer commercial/payer pathways drive a re‑rating to the high end of broker ranges. With consensus clustered near the mid‑$70s, the bull target (~$100) is achievable only if multiple positive catalysts align or strategic partnership/M&A interest materializes.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Capital/dilution risk from financing needs
Momentum
18
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $75.00 · Bull $100.00 · Bear $33.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-13 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $78.77
Why
Momentum18 · Δ7d +0.0
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
18
34% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+4.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade C. Momentum 18.1 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.44B
Beta
1.16
Shares Out
70.03M
P/E (TTM) · Derived
-7.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-10.36
Rev YoY
-
EPS YoY
-48.0%
Gross Margin
-
Op Margin
-
Net Debt
-$590.17M
Current Ratio
12.21
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology